Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5573_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Foreword
- •Foreword
- •Contents of Volume I
- •Contents of Volume II
- •Contributors
- •1.1 Introduction
- •1.4.3 Acute Stroke
- •1.4.4 CNS Infection
- •1.4.1 Sepsis
- •1.4.2 Acute Encephalopathy
- •1.4.5 Severe Community-Acquired Pneumonia
- •1.4.6 Nosocomial Pneumonia
- •1.4.7 Pulmonary Edema
- •1.4.8 Fever
- •References
- •2.1 Introduction
- •2.4 ECG Nomenclature
- •2.4.1 P Wave
- •2.4.2 PR Interval
- •2.4.3 QRS Complex
- •2.4.4 J Point
- •2.4.5 ST Segment
- •2.4.6 T Wave
- •2.4.7 QT Interval
- •2.4.8 U Wave
- •2.4.9 RR Interval
- •2.5.1 P Wave
- •2.5.1.1 Atrial Arrhythmias
- •Atrial Fibrillation
- •Atrial Flutter
- •Atrial Tachycardia
- •Multifocal Atrial Tachycardia
- •2.5.1.2 Interatrial Blocks
- •Intermittent Interatrial Block (I-IAB)
- •Advanced Interatrial Block (A-IAB)
- •2.5.2 P-QRS Ratio
- •2.5.2.1 Shortened P-QRS Ratio
- •Wolff-Parkinson-White Syndrome (WPW)
- •Junctional Rhythm
- •Atrioventricular Nodal Reentrant Tachycardia (AVNRT)
- •2.5.2.3 Prolonged P-QRS Ratio
- •2.5.3 PR Interval
- •2.5.3.1 Shortened PR Interval
- •2.5.3.2 Prolonged PR Interval
- •2.5.3.3 Second-Degree AV Block
- •Advanced AV Block
- •Third-Degree AV Block (Complete Heart Block)
- •2.5.4 PR Segment
- •2.5.4.1 PR-Segment Elevation
- •2.5.4.2 PR-Segment Depression
- •Acute Pericarditis
- •Acute Myocardial Ischemia
- •2.5.5 Q Waves
- •2.5.6 QRS Complex
- •2.5.6.1 Heart Rate
- •2.5.7 QT Interval
- •2.5.8 ST Segment
- •2.5.8.1 ST-Segment Depression
- •2.5.8.2 ST-Segment Elevation
- •2.5.9 T Waves
- •2.5.9.1 Inverted T Wave
- •2.5.9.2 Flattened T Wave
- •2.5.9.3 Peaked T Wave
- •References
- •Further Reading
- •3.1 Introduction
- •3.2.2 Nasogastric Tube
- •3.2.3 Central Venous Catheters
- •3.2.4 Cardiac Devices
- •3.2.5 Arterial Catheters
- •3.3 Cardiopulmonary Abnormalities
- •3.3.1 Pulmonary Edema
- •3.3.2 Acute Respiratory Distress Syndrome
- •3.3.3 Atelectasis
- •3.3.4 Aspiration
- •3.3.5 Pneumonia
- •References
- •4.1 Introduction
- •4.5 Modes of Mechanical Ventilation
- •4.5.1 Volume Control Ventilation
- •4.5.2 Pressure Control Ventilation
- •4.5.3 Pressure Support Ventilation
- •4.6 Patient-Ventilator Interactions
- •4.6.1 Trigger Dyssynchrony
- •4.6.2 Flow Dyssynchrony
- •4.6.3 Cycle Dyssynchrony
- •4.9.1 Acute Respiratory Distress Syndrome
- •4.9.2 Severe Asthma Exacerbation
- •4.11 Summary
- •5.10 Neuromuscular Blockade
- •References
- •5.1 Introduction
- •5.3 Pathobiology
- •5.4 ARDS Phenotypes
- •5.5 Lung-Protective Ventilation
- •5.6 Positive End-Expiratory Pressure
- •5.7 Conservative Fluid Management
- •5.8 Moderate-to-Severe ARDS
- •5.9 Prone Positioning
- •5.11 Corticosteroids
- •5.12 Inhaled Pulmonary Vasodilators
- •5.13 Veno-Venous Extracorporeal Membrane Oxygenation
- •5.14 Survivorship
- •References
- •6.1 Introduction/Epidemiology
- •6.2 Physiology
- •6.2.2 Physiology During COPD Exacerbation
- •6.4 Pharmacologic Treatment
- •6.4.1 Bronchodilators
- •6.4.1.1 Mechanism
- •6.4.2 Glucocorticoid Therapy
- •6.4.2.1 Mechanism
- •6.4.2.4 Duration
- •6.4.3 Antimicrobials
- •6.4.3.1 Antibiotic Patient Selection
- •6.4.4.1 Nonpharmacologic Interventions
- •6.4.4.2 Opioids
- •6.4.4.3 Benzodiazepines
- •6.4.4.4 Dexmedetomidine
- •6.4.4.5 Ketamine
- •6.4.5 Adjunctive Therapies
- •6.4.5.1 Magnesium
- •6.4.5.3 Vitamin D
- •6.4.5.4 Venous Thromboembolism Prophylaxis
- •6.4.5.5 Smoking Cessation
- •6.4.5.6 Bowel Regimen
- •6.4.5.7 Mucolytics
- •6.4.5.8 Nutrition
- •6.4.5.9 Post-Discharge Adjuncts
- •6.5 ICU-Level Interventions
- •6.5.1 Noninvasive Positive-Pressure Ventilation
- •6.5.2 High-Flow Nasal Canula
- •6.5.3 Invasive Mechanical Ventilation
- •6.6 Conclusion
- •References
- •7.1 Introduction
- •7.1.1 What Is Asthma?
- •7.2 Diagnosis
- •7.2.1 Physical Examination
- •7.2.2 Laboratory Data
- •7.2.3 Radiographic Findings
- •7.3.1 Standard-of-Care Therapy
- •7.3.3 Potential Adjunctive Therapies
- •7.3.3.1 Inhaled Corticosteroids (ICSs)
- •7.3.3.4 Intravenous (IV) Aminophylline
- •7.3.3.5 Intravenous (IV) Beta2-Agonists
- •7.3.3.6 Leukotriene Antagonists (LTRAs)
- •7.3.3.7 Intramuscular (IM) or IV Epinephrine
- •7.3.3.8 Inhaled Anesthetics
- •7.3.3.9 Inhaled Helium-Oxygen (Heliox)
- •7.3.3.10 Intravenous Ketamine
- •7.3.4.1 Subcutaneous (SC) Biologics
- •7.4.1 Noninvasive Ventilation (NIV)
- •7.4.2 Invasive Mechanical Ventilation (IMV)
- •7.6.1 Outpatient Follow-Up
- •7.7 Summary
- •References
- •8.1 Introduction
- •8.1.3.2 Anatomic Location
- •8.1.3.3 Chronicity
- •8.1.4 Clinical Presentation
- •8.1.4.1 Symptoms
- •8.1.4.2 Physician Examination
- •8.1.4.3 Cardiopulmonary Compromise
- •8.2.1.1 Clinical Pretest/Scores
- •8.2.1.2 D-Dimer-Level Interpretations
- •8.2.2 Computed Tomography Pulmonary Angiography (CTPA)
- •8.2.3 Mortality Risk Assessment
- •8.2.3.1 PE Severity Index Score
- •8.2.3.2 Prognostic Indicators
- •8.3.2 High-Risk PE
- •8.4 Systemic Thrombolytic Therapy
- •8.4.1.1 High-Risk PE
- •8.4.1.2 Intermediate-Risk PE
- •8.4.1.3 Cardiac Arrest
- •8.5.2 Percutaneous Mechanical Interventions
- •8.5.2.2 Catheter-Directed Thrombolysis
- •8.5.3 Surgical Embolectomy
- •8.5.4 Mechanical Circulatory Support
- •8.6.1 PE Response Team (PERT)
- •8.6.3.1 Renal Dysfunction
- •8.6.3.4 Cancer
- •8.6.3.5 Treatment Failure
- •8.7 Conclusion
- •References
- •9.1.2 ECMO Outcomes
- •9.2 ECMO During Cardiopulmonary Resuscitation (eCPR)
- •9.2.1 Extracorporeal Carbon Dioxide Removal
- •9.3 ECMO Management
- •9.3.3 Fluid Management
- •9.4.1 Coagulation Changes
- •9.4.2 Transfusion Thresholds
- •9.4.3.1 Heparin
- •9.4.3.2 Direct Thrombin Inhibitors
- •9.4.4 Monitoring Anticoagulation
- •9.6.2.1 Opioids
- •9.6.2.2 Ketamine
- •9.6.2.3 Propofol
- •9.6.2.4 Benzodiazepines
- •9.6.2.5 Dexmedetomidine
- •9.7.1 Aminoglycosides
- •9.7.2 Beta-Lactams
- •9.7.4 Antifungals
- •9.9 Other Complications
- •9.9.1 Bleeding
- •9.9.2 Thrombosis
- •9.9.3 Neurologic
- •9.10 Conclusion
- •References
- •10.1 Type 1–5 Myocardial Infarctions
- •10.2 Acute Coronary Syndrome (Type 1 MI)
- •10.3 Clinical Presentation/Evaluation
- •10.4 Non-pharmacologic Therapy
- •10.5 Pharmacologic Therapy
- •10.5.1 Fibrinolytics
- •10.5.2 Anticoagulants
- •10.5.2.1 Heparins
- •10.5.2.2 Direct Thrombin Inhibitors
- •10.5.3 Antiplatelets
- •10.5.3.1 Aspirin
- •10.5.3.2 P2Y12 Inhibitors
- •Clopidogrel
- •Prasugrel
- •Ticagrelor
- •10.5.3.3 Glycoprotein IIb/IIIa Receptor Inhibitors
- •10.5.3.4 Cangrelor
- •10.7 Long-Term Management
- •10.7.1 High Bleed Risk (HBR)
- •10.7.2 Statins
- •10.7.3 Beta-Blockers
- •10.7.5 Mineralocorticoid Receptor Antagonists
- •References
- •11.1 Introduction
- •11.2.2 What is Ejection Fraction?
- •11.4 Understanding Blood Pressure
- •11.5 Preload vs. Afterload
- •11.6 Acute Decompensated Heart Failure
- •11.6.2 Etiology
- •11.8 Treating Volume Overload
- •11.8.1 Loop Diuretics
- •11.9 Intravenous Vasodilators
- •11.10 Cardiogenic Shock
- •11.10.1 Inotrope Clinical Pearl
- •11.12 Digoxin
- •11.12.3 Loading Dose
- •11.12.4 Maintenance Dosing
- •11.12.5 Monitoring
- •11.12.7 Distribution
- •11.12.8 Drug-Drug Interactions
- •11.12.9 Digoxin Toxicity
- •11.13 ADHF Clinical Pearls
- •11.13.3 Avoid Phenylephrine
- •11.13.4 Use Mean Arterial Pressure (MAP)
- •11.14 Guideline-Directed Medical Therapy
- •11.15 Venous Thromboembolism (VTE) Prophylaxis
- •11.16 Conclusion
- •References
- •12.1 Introduction
- •12.3 Diagnostic Findings
- •12.4.1 Oxygen Therapy
- •12.4.2 Pharmacological Management
- •12.4.3 Mechanical Circulatory Support (MCS)
- •12.5 Pulmonary Hypertension
- •12.6 The Pharmacist’s Role
- •12.7 Conclusion
- •References
- •13.1 Introduction
- •13.2 Atrial Arrhythmias
- •13.2.2 Atrioventricular Blocks
- •13.2.3 Atrial Fibrillation
- •13.2.3.2 Anticoagulation
- •13.2.3.3 Rate vs. Rhythm Control
- •13.2.4 Atrial Flutter
- •13.2.5 Supraventricular Tachycardia (SVT)
- •13.3 Ventricular Arrhythmias
- •13.3.1 Premature Ventricular Complexes
- •13.3.2 Ventricular Tachycardia
- •13.3.2.1 Torsades de Pointes
- •13.3.3 Ventricular Fibrillation
- •13.3.4 Ventricular Arrhythmia Treatment Strategies
- •13.3.4.1 ICD Implantation
- •13.3.4.2 Pharmacologic Treatments
- •13.3.4.3 Catheter Ablation
- •13.4 Conclusion
- •References
- •14.1 Introduction
- •14.3.2 Laboratory Assessment
- •14.3.3 Imaging
- •14.3.4 Invasive Hemodynamic Monitoring
- •14.4.1 Distributive
- •14.4.2 Cardiogenic
- •14.4.3 Hypovolemic
- •14.4.4 Obstructive
- •14.5 Management
- •14.6 Conclusion
- •References
- •15.1 Background
- •15.2 Diagnosis
- •15.3 Management
- •References
- •16.1 Introduction
- •16.3 Hemodynamics
- •16.5 Pharmacological Management
- •16.5.1 Hyperosmolar Therapy
- •16.5.3 Barbiturate Coma
- •16.6 Nonpharmacological Treatments
- •16.6.2 Temperature Management
- •16.6.3 Prophylactic Hypothermia
- •16.7 Adjunct Therapies
- •16.7.2 Venous Thromboembolism (VTE) Prophylaxis
- •16.7.3 Antibiotic Prophylaxis
- •16.7.4 Stress Ulcer Prophylaxis (SUP)
- •16.7.5 Tranexamic Acid
- •16.7.6 Glucose Targets
- •16.7.7 Steroids
- •16.8 Complications
- •16.8.1 Paroxysmal Sympathetic Hyperactivity
- •16.8.3 Central Fever
- •16.8.4.1 Diabetes Insipidus
- •16.8.4.3 Cerebral Salt Wasting Syndrome
- •16.9 Conclusion
- •References
- •17.1 Introductory Case
- •17.2 Introduction
- •17.4 Pathophysiology
- •17.5 Acute Therapies
- •17.5.1 Thrombolytic Therapy
- •17.5.2 Thrombectomy
- •17.5.3 Blood Pressure Management
- •17.5.4 Acute Anticoagulation
- •17.5.5 Antiplatelet Therapy
- •17.6 Early Complications
- •17.6.1 Hemorrhagic Conversion
- •17.6.2 Angioedema
- •17.6.3 Malignant Cerebral Edema
- •17.7 Secondary Prevention
- •References
- •18.1 Introduction
- •18.4 Therapeutic Drug Monitoring
- •18.5 Adverse Drug Effects
- •18.7 Anti-seizure Medications
- •18.7.1 Available Parenteral Preparations
- •18.7.1.1 Benzodiazepines: GABAA Receptor Activation
- •18.7.1.2 Other GABAergic Therapies
- •Barbiturates: GABAergic
- •Phenobarbital
- •Pentobarbital Infusion
- •Propofol Infusion: GABAergic
- •18.7.1.3 Second-Line Non-anesthetic ASMs
- •Levetiracetam: Synaptic Vesicle Protein 2A Binding

Chapter 8
Acute Pulmonary Embolism
SoyoungKristiKim andLaurenA.Igneri
8.1 Introduction
Pulmonary embolism (PE) is a common yet serious clinical presentation of venous
thromboembolism (VTE). VTE, including deep vein thrombosis (DVT) and PE, is
the third most common acute cardiovascular syndrome globally, behind myocardial
infarction and stroke [59]. Globally, the incidence of PE is reported to be between
39 (in Hong Kong) and 115 (in the United States) per 100,000 population [113].
Acute PE may present with varying degrees of critical illness, ranging from incidental ndings of asymptomatic PE to hemodynamic instability or cardiac arrest in
high-risk patients with PE.Despite numerous advancements in the management of
PE, the mortality rate for PE continues to be high. In high-risk patients, the 30-day
mortality can be as high as 22% [73]. An analysis of epidemiologic databases
reported the overall age-adjusted mortality per 100,000 populations as 2.84in 2006
compared to 2.81in 2019 [118].
Given the incidence and severity of illness associated with PE, pharmacist clinicians should have an expanded understanding of the diagnostic process for the
detection and management of PE.Pharmacists should be aware of the high rates of
VTE that are associated with critical illness and develop during hospitalization.
Hospital-acquired VTE accounts for more than half of all VTE reported in the
United States [38]. The incidence of PE in critically ill patients in the intensive care
unit (ICU) ranges from 1.4% to 2.9%, although the true incidence including undetected or asymptomatic PE may be higher [73].
S. K. Kim · L. A. Igneri (*)
Clinical Pharmacy Specialist, Critical Care, Department of Pharmacy,
Cooper University Health Care, Camden, NJ, USA
e-mail: Igneri-Lauren@CooperHealth.edu
Switzerland AG 2025
Y. Alzaidi, M. A. Gebily (eds.), The Pharmacist’s Expanded Role in Critical
Care Medicine, https://doi.org/10.1007/978-3-031-77335-8_8
171© The Author(s), under exclusive license to Springer Nature

172
S. K. Kim and L. A. Igneri
8.1.1 Risk Factors forVTE
Risk factors for the development of VTE are characterized as either acquired or
inherited. Acquired risk factors include comorbidities such as hypertension, recent
surgery, immobility, cancer, and obesity [101]. Patients may also have inherited risk
factors for hypercoagulable states. The concept of antithrombin deciency leading
to the loss of thrombin activity was proposed as early as 1905, forming the basis for
there being genetic risk factors for VTE [22, 101]. Additional risk factors for inherited thrombophilia include factor V Leiden mutation, prothrombin gene mutation,
and deciencies in protein S or C [22]. The identication of reversible or irreversible acquired risk factors will play an important role in delineating provoked and
unprovoked VTE, which determines the duration of anticoagulation therapy [59].
Table8.1 describes the weak, moderate, and strong predisposing factors for VTE.
8.1.2 Pathophysiology ofVTE
VTE often results from the presence of optimal conditions for thrombus formation
as described by Virchow’s triad. This includes alterations in blood ow (e.g., venous
stasis), endothelial damage, and hypercoagulable state as described above [101].
Table 8.1 Predisposing factors for VTE
Weak risk
factors Moderate risk factors Strong risk factors
Diabetes
mellitus
Hypertension
Immobility/bed
rest
Increasing age
Laparoscopic
surgery
Obesity
Pregnancy
Varicose veins
Arthroscopic knee surgery
Autoimmune diseases
Blood transfusion
Central venous lines
Intravenous catheters and leads
Chemotherapy
Congestive heart failure or respiratory
failure
Erythropoiesis-stimulating agents
Hormone replacement therapy
(depends on formulation)
In vitro fertilization
Oral contraceptive therapy
Post-partum period
Infection (specically pneumonia,
urinary tract infection, and HIV)
Inammatory bowel disease
Cancer (highest risk in metastatic
disease)
Paralytic stroke
Supercial vein thrombosis
Thrombophilia
Fracture of lower limb
Recent hospitalization for heart
failure or atrial brillation/utter
Hip or knee replacement
Major trauma
Myocardial infarction
Previous VTE
Spinal cord injury

8 Acute Pulmonary Embolism
173
Thrombi typically form in the deep veins of the lower extremities, usually at sites of
decreased ow such as valve cusps. Once microthrombi are formed due to venous
stasis or endothelial injury, blood ow is further impeded. This progresses to further
vascular injury and clot formation, perpetually activating the coagulation cascade
[71]. Thrombus that originates from a venous bed may resolve completely or partially via recanalization, organization, and/or lysis or continue to expand and embolize to the pulmonary circulation [71, 101].
8.1.3 PE Denitions andClassications
8.1.3.1 Pathogenesis ofPE
PE often results from a thrombus originating in the lower extremity proximal veins
(e.g., iliac, femoral, or popliteal) that travels to the pulmonary vasculature. Emboli
follow normal venous circulation, from the vena cava to the right atrium and ventricle, and then ultimately to the pulmonary artery and its branches. The presence of
specic patient factors such as the use of pacemakers, implantable debrillators,
and indwelling central venous catheters may increase the risk of an upper extremity
DVT that embolizes the pulmonary arteries [71, 101]. In the Registro Informatizado
de la Enfermedad Tromboembolica (RIETE) registry of patients with documented
VTE, the rates of PE at 90days were similar regardless of the origin of the thrombus
in the upper or lower extremity [74]. In rare instances, thrombus may originate
directly from the pulmonary vasculature without evidence of DVT.Factors such as
endothelial cell dysfunction, hypoxia, and inammation may lead to this phenomenon of in situ PE. This can be observed in patients with trauma (such as chest
contusions), sickle cell disease, pulmonary tuberculosis, and other systemic diseases. Seldom, pulmonary embolism develops from non-thrombotic causes, such as
air, fat, or tumor emboli that obstruct the pulmonary artery or its branches [71, 110].
The pathophysiology, diagnosis, and management of non-thrombotic PE are beyond
the scope of this chapter. There are multiple ways to characterize PE, including its
anatomic location, chronicity, and risk stratication, which are described in
Table8.2.
8.1.3.2 Anatomic Location
The anatomic location of thrombi further straties PE.A large clot that lodges at the
bifurcation of the main pulmonary artery leads to a saddle PE.A saddle embolus
obstructs the blood ow to both the right and left pulmonary arteries. Smaller
emboli that travel beyond the pulmonary artery bifurcation can lodge distally in the
lobar, segmental, or subsegmental branches. Occlusions of a distal pulmonary artery
(segmental and subsegmental) can lead to pulmonary infarction, potentially causing
ischemia, hemorrhage, and tissue necrosis. Due to the location of the emboli, saddle

174
Table 8.2 Characterization of PE
Characteristics Categories Denition
Anatomic Saddle Emboli at the bifurcation of the main pulmonary artery
Lobar Emboli at the lobar branches
Segmental Emboli at the segmental branches
Subsegmental Emboli at the subsegmental branches
Chronicity Acute Immediate or recent symptoms
Subacute Symptoms over weeks to months
Chronic Symptoms lasting months to years
Risk Low Refer to Table8.5
Intermediate-
ow
l
Intermediate-
high
High
S. K. Kim and L. A. Igneri
PE was historically assumed to be associated with more hemodynamic compromise
compared to PE caused by distal thrombi. However, no difference in mortality was
observed between a saddle and non-saddle PE in a recent retrospective review,
which highlights the importance of cautiously monitoring all patients for signs of
decompensation regardless of the anatomic location of the emboli [41].
8.1.3.3 Chronicity
Patients can present with acute, subacute, or chronic PE.The duration of patient
symptoms such as cough or shortness of breath differentiates patients into one of the
three categories. Patients with acute PE present with immediate or recent symptoms, whereas those with subacute PE may report symptoms that are presented
insidiously over weeks to months [26, 96]. In contrast, patients with chronic PE
often present with symptoms lasting months to years. Although most patients
recover fully after the resolution of acute embolism, approximately 30–50% of
patients have perfusion defects and residual pulmonary obstruction at 6months
from diagnosis despite anticoagulation [115].
Patients with chronic PE may develop pulmonary hypertension from unresolved
pulmonary occlusions in the pulmonary arteries, subsequent brosis, and remodeling of the pulmonary vessels leading to elevated pulmonary vascular resistance
(PVR) [76]. This unique pathophysiology is known as chronic thromboembolic pulmonary hypertension (CTEPH), also designated as Group 4 pulmonary hypertension by the World Health Organization. Although the incidence of CTEPH is not
clearly dened, it is identied in 0.5–9% of patients following acute PE [115].
Treatment for CTEPH can be highly variable and requires multidisciplinary
team evaluation. All eligible patients without contraindications should receive
indenite anticoagulation. For patients that are operable candidates, pulmonary

8 Acute Pulmonary Embolism
175
thromboendarterectomy (PTE) may be a curative therapy. In recent years, balloon
pulmonary angioplasty emerged as an established treatment option for patients who
are not surgical candidates [115]. Patients may also receive pulmonary hypertensionspecic therapies, such as pulmonary vasodilators or remodeling agents that lower
the pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP)
[52]. Riociguat, a soluble guanylate cyclase stimulator approved for use in inoperable CTEPH or persistent CTEPH following PTE, was shown to improve 6-minute
walking distance and PVR in the CHEST-1 study [33].
8.1.3.4 Risk Stratication
Patients are further categorized according to the risk of mortality and poor outcomes. Previously, PE was often stratied as massive, submassive, or nonmassive/
low risk depending on the hemodynamic stability, although denitions of hemodynamic stability have varied. The 2011 scientic statement from the American Heart
Association dened massive PE as an acute PE with sustained hypotension, pulselessness, or persistent profound bradycardia. The term submassive PE was utilized to
describe acute PE without systemic hypotension but with either RV dysfunction or
myocardial necrosis, and low-risk PE was dened as acute PE in the absence of the
clinical markers of adverse prognosis that dene massive or submassive PE [42].
These denitions are important to acknowledge since historical primary literature
frequently utilized such terminology to stratify patients. Newer guidelines, including the one published by the European Society of Cardiology in 2020, transitioned
to categorizing PE as high, intermediate-high, intermediate-low, and low risk [59].
The risk stratication ultimately guides diagnostic and treatment strategies in PE,
which are discussed in forthcoming sections.
8.1.4 Clinical Presentation
8.1.4.1 Symptoms
Patients with acute PE may present with a multitude of nonspecic symptoms or
with abnormal cardiopulmonary exams that mimic numerous other disease states
including:
• Pleuritic chest pain
• Dyspnea
• Apprehension
• Angina chest pain
• Cough
• Diaphoresis
• Hemoptysis

176
S. K. Kim and L. A. Igneri
• Lightheadedness
• Leg or thigh pain/swelling
• Orthopnea
• Palpitations
• Syncope
• Wheezing
PE should be included in the differential diagnosis when unexplained or rapidonset dyspnea, pleuritic chest pain, or hemoptysis is present. Particularly, in patients
with preexisting heart or pulmonary disease, dyspnea may be the most prominent
symptom. However, dyspnea was experienced by 73% of patients with PE despite
no preexisting cardiopulmonary conditions in the PIOPED II registry, at rest or with
exertion [98]. Pleuritic chest pain is typically the result of pleural irritation from
distal emboli that causes pulmonary infarction, whereas chest pain that mimics
acute coronary syndrome or aortic dissection may be caused by RV ischemia from
extensive central PE [101]. Symptoms suggestive of DVT (e.g., erythema, warmth,
pain, swelling, tenderness) may also warrant further evaluation for PE, as PE often
arises from a thrombus in the lower extremity. In the same registry, 44% of patients
with PE experienced concomitant leg or thigh symptoms [98].
Patients with high-risk PE may present with hemodynamic instability such as
systemic hypotension, RV dysfunction, presyncope or syncope, and even cardiopulmonary arrest [59, 101]. These features are more pronounced in patients with a
greater magnitude of embolism or in patients with preexisting cardiac comorbidities
[59, 101]. Finally, some patients with PE may be asymptomatic on presentation,
making workup challenging.
8.1.4.2 Physician Examination
Similarly to presenting symptoms, patients with PE may have variable physical
exam ndings that mimic other disease states [101]:
Anxiety
•
• Chest-w
Fever
•
all tenderness
• Heart failure
Le
•
g or thigh swelling/tenderness
Neck v
•
•
ein distention
Shock
• Tachycardia
• Tachypnea
• Wheezing
Patients with PE frequently present with tachypnea and tachycardia, which may
confound the diagnoses by mimicking potential infectious etiologies. Particularly
when patients have concomitant fever or shock, the treatment team may focus the

8 Acute Pulmonary Embolism
177
management on antimicrobials for pneumonia or sepsis. The pharmacist’s involvement in the appropriate evaluation of these nonspecic clinical ndings can minimize unnecessary antimicrobial usage in patients with PE.
The severity of a patient’s physical examination may depend on the patient’s
baseline cardiopulmonary reserve. Patients with a concomitant cardiac or pulmonary disease may not possess the adequate compensatory mechanism to overcome
the clot burden in the pulmonary vasculature, leading to worsening hemodynamics
[71, 101].
8.1.4.3 Cardiopulmonary Compromise
Pulmonary embolism may impair not only gas exchange, but also systemic circulation [59]. Whereas small emboli block the peripheral arteries and precipitate pulmonary infarction, large saddle embolus can obstruct the main pulmonary artery and
have a grave impact on the cardiovascular system.
Hypoxemia from PE develops due to various mechanisms. The obstruction of the
pulmonary vascular bed causes decreased capillary blood ow, leading to intrapulmonary shunting, increased alveolar dead space, ventilation-perfusion (V/Q) ratio
mismatch, and decreased mixed venous oxygen saturation. V/Q mismatch occurs
from zones of reduced ow in the obstructed vessels and zones of overow in nonobstructed vessels. Atelectasis, alveolar hemorrhage, or bronchoconstriction can
also lead to worsening shunt physiology [101, 110]. Low CO from RV failure also
contributes to the reduced mixed venous oxygen saturation.
PE may cause hemodynamic alterations to varying degrees. When less than 20%
of the pulmonary vascular bed is occluded by thromboemboli, patients without preexisting cardiopulmonary disease are able to elicit compensatory mechanisms to
support near-normal hemodynamics [101]. PE-induced hypoxemia causes neurohormonal activation of thromboxane A2 and serotonin, leading to initial vasoconstriction and increased PVR. When 30–40% of the pulmonary bed is occluded, PAP
increases, and the RV adapts by increasing the stroke volume to maintain cardiac
output (CO). This compensatory mechanism temporarily improves ow through the
obstructed pulmonary vascular bed and stabilizes systemic blood pressure. However,
the effect is short-lived as the thin-walled RV cannot generate a consistent mean
PAP >40mmHg. When pulmonary obstruction exceeds 50–60%, or when the compensatory mechanism is overwhelmed, drastic cardiovascular collapse can ensue.
The increase in PVR leads to RV dilation, increased RV wall tension, and attening
of the interventricular septum, which alter the contractility of the myocardium.
Ultimately, abrupt RV failure and desynchronization of the ventricles result in LV
lling impedance, reduction in CO, and hemodynamic instability [101]. RV failure
is attributed as the main cause of death in severe PE [59]. Patients with preexisting
cardiopulmonary disease may have an exaggerated response to smaller degrees of
pulmonary vascular occlusion, leading to severe pulmonary hypertension disproportionate to the degree of obstruction from acute PE [101].

178
8.2 Diagnosis andRisk Assessment
S. K. Kim and L. A. Igneri
8.2.1
8.2.1.1 Clinical Pretest/Scores
Clinical pretest probability scoring is a cornerstone of diagnostic algorithms for PE
as it guides selection of tests based on an assessment of the patient’s signs and
symptoms, risk factors for PE, presence of DVT, and whether PE is the most likely
diagnosis, thereby allocating resources to patients most likely to derive benet from
testing (e.g., conrm or refute diagnosis of PE) [59]. Comparatively, pretest assessment using clinical gestalt lacks standardization, and preference should be to use
clinical prediction rules for workup of PE.
ability scores as they inform the need for further diagnostic testing and provide an
opportunity to strategize potential initial anticoagulation selection while conrmatory tests are pending. The most widely used clinical pretest scores for PE include
the Wells scores, Geneva Clinical Prediction, and PE Rule-Out Criteria and are
compared in Table8.3.
estimate the clinical pretest probability of PE as either low, moderate, or high and is
one of the most widely utilized and validated pretest probability scoring tools for PE
[111, 112]. In the study validating the score in the emergency department (ED), PE
was excluded in patients with a low pretest score and negative D-dimer and no
imaging was performed. Comparatively, 40.6% of patients in the high-probability
group and 16.2% in the moderate-probability group with positive D-dimer were
diagnosed with PE.Only 1.3% of patients in the low-probability group re-presented
back to the ED and were ultimately diagnosed with PE [112]. Subsequently, the
score was simplied to “PE unlikely” or “PE likely” and validated in the Christopher
Study [106]. In patients classied as unlikely, PE was excluded if the D-dimer was
normal, and most patients did not receive anticoagulation. Only 0.5% were found to
have subsequent PE at 3-month follow-up [106]. This score was also validated in
conjunction with the use of an age-adjusted D-dimer cutoff in ADJUST-PE, a multicenter, multinational prospective management outcome study of outpatients with
suspected PE [88]. Similarly, the Geneva clinical prediction rule, which originally
incorporated seven variables, was revised to eight variables, simplied, and then
validated in the ADJUST-PE [88].
the Pulmonary Embolism Rule-Out Criteria (PERC) were developed to identify
those with a low risk for PE who do not require further workup [59]. When there is
low clinical suspicion for PE and the patient meets all eight criteria, a diagnosis of
PE should not be pursued. Penaloza and colleagues found that when all PERC criteria were met in patients with a low gestalt assessment, PE prevalence was zero
[80]. Subsequently, a prospective, observational study demonstrated that PERC had
Diagnostic
The pharmacist clinician should be familiar with the most common pretest prob-
The Wells score incorporates seven criteria with the evaluation of D-dimer to
To prevent unnecessary testing for PE in the emergency department (ED) setting,
Workup

8
cute Pulmonary Embolism
A
179
Table 8.3
88, 111, 112]
Wells Score Geneva Clinical Prediction
Variables Points Variables
Clinically
suspected DVT
Alternative
diagnosis is less
likely than PE
Heart rate >100
beats/min
Immobilization or
surgery in
previous 4weeks
History of VTE 1.5 Active cancer 2 1 No hemoptysis
Hemoptysis 1 Unilateral
Malignancy or
treatment for it in
previous 6months
Interpretation
Clinical
Probability Points
Three-level
prediction
High
Two-level
prediction
High
Comparison of
probability
Moderate
probability
Low probability ≤4
probability
Low probability ≤4
Wells scores, Geneva Clinical Prediction, and PE Rule-Out Criteria [59,
PE Rule-out
Criteria Rule
Clinical Decision
Rule Points
VariablesOriginal Simplied
3 Previous PE or
3 Heart rate Pulse <100 beats/
1.5 Surgery or fracture
1.5 Hemoptysis 2 1 No unilateral leg
1 Pain on lower-limb
≥6.5 Low 0–3 0–1
4.5–
6.0
>4 PE unlikely 0–5 0–2
DVT
75–94 beats/minute 3 1
≥95 beats/minute 5 2
within past month
lower-limb pain
deep venous
palpation and
unilateral edema
Age>65 1 1 No oral hormone use
Clinical
Probability Points Clinical Probability
Three-level score If all variables met
Intermediate 4–10 2–4
High ≥11 ≥5
Two-level score
PE likely ≥6 ≥3
3 1 Age <50years
minute
2 1 Pulse oximetry
>94%
swelling
3 1 No surgery or trauma
within 4weeks
4 1 No prior DVT or PE
combined with low
clinical suspicion for
PE, diagnosis of PE
should not be
pursued

180
S. K. Kim and L. A. Igneri
a low rate of false-negatives for excluding PE in low-risk patients, and a crossover
cluster-randomized trial found that PERC was noninferior to the gestalt method
[30, 81].
8.2.1.2 D-Dimer-Level Interpretations
D-dimer levels become elevated in acute thrombosis due to activation of the coagulation cascade and plasmin-mediated enzymatic degradation of cross-linked brin
clot [50]. While normal D-dimer levels (generally <500ng/mL) have a high negative predictive value to rule out PE, high D-dimer levels have a low positive predictive value and are not useful as a conrmatory test [59].
Several D-dimer assays are available, but the quantitative enzyme-linked immunosorbent assay (ELISA) has >95% sensitivity to exclude PE in patients with low or
intermediate pretest probability. Many studies have shown that a negative D-dimer in
combination with low or intermediate clinical pretest probability scores excludes PE
without the need for further testing [30, 80, 81, 88, 112]. When anticoagulation is
withheld due to the negative result, the risk of developing PE at 3months is <1% [14].
It is important for the pharmacist clinician to be aware of disease states that may
cause false elevations in D-dimer to aid with the interpretation of result, especially
when used in conjunction with pretest probability scoring. Other physiologic states
or conditions that may result in elevated D-dimer in the absence of VTE include
pregnancy, malignancy, cigarette smoking, trauma, infection, or sepsis. Additionally,
patients who are older, immobilized, and with autoimmune disorders or have had
recent surgery may have an elevated D-dimer without having VTE [12].
Recently, alternative D-dimer thresholds have been evaluated to optimize the
proportion of patients who ultimately receive conrmatory imaging studies and are
found to have PE.
Several studies have shown that D-dimer levels increase with age, limiting the utility of D-dimer thresholds <500ng/mL to rule out PE in older individuals, especially
those greater than age 80. The age-adjusted D-dimer threshold of patient age multiplied by 10ng/mL in individuals over age 50 has been prospectively evaluated. In the
ADJUST-PE study, clinical pretest probability scoring was evaluated with either the
simplied Geneva score or the two-level Wells score. Patients with low/intermediate
or unlikely probability had D-dimer testing performed, with a negative test dened as
<500ng/mL (patient age <50) or less than the age-adjusted level (patient age ≥50). In
patients with D-dimer between 500 and their age-adjusted threshold, the rate of VTE
at 3months was 0.3%. Among patients >75years, the use of age-adjusted D-dimer
increased the proportion of patients in whom PE could be excluded from 6.4% with
the standard threshold to 29.7% without any additional false-negative ndings [88].
Due to the risks associated with radiation and contrast media, clinical probabilityadapted D-dimer thresholds have been evaluated to reduce exposure to conrmatory
testing in patients unlikely to have PE.The PEGeD study used the Wells clinical
pretest probability scoring with D-dimer <1000 ng/mL in low-probability and
<500ng/mL in moderate-probability patients to exclude PE and further workup in
Соседние файлы в папке Библиотека им академика М.И. Перельмана
